7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Rain Oncology Inc.
(NASDAQ:RAIN) 

RAIN stock logo

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p5...

Founded: 2017
Full Time Employees: 63
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Rain Oncology Op Cashflow Per Share ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.26-1.94-1.61-1.29-0.97-0.65-0.320
Rain Oncology Free Cashflow Per Share ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.26-1.94-1.61-1.29-0.97-0.65-0.320
Rain Oncology Cash Per Share ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.671.3322.663.3344.66
Rain Oncology (GAAP) P/E ratio ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -3.78-3.24-2.7-2.16-1.62-1.08-0.540
Rain Oncology P/B ratio ttm
202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.360.721.081.441.82.152.51
No extra charts and metrics for this ticker.